Immunotherapeutic agents against amyloid beta (Aβ) are associated with adverse events, including amyloidrelated imaging abnormalities with edema and effusion (ARIA-E). Recently, a magnetic resonance imaging (MRI) rating scale was developed for ARIA-E detection and classification. The aim of this study was to validate the use of this rating scale in a larger patient group with multiple raters. METHODS: MRI scans of 75 patients (29 with known ARIA-E and 46 control subjects) were analyzed by five neuroradiologists with different degrees of expertise, according to the ARIA-E rating scale. For each patient, we included a baseline and a follow-up fluid-attenuated inversion recovery image. Interrater agreement was calculated using intraclass correlation coefficient (ICC). RESULTS: On average, 4.1% of the ARIA-E cases were missed. We observed a high interrater agreement for scores of sulcal hyperintensity (SH; ICC = .915; 95% CI 85-95) and for the combined scores of the 2 ARIA-E findings, parenchymal hyperintensity (PH) and SH (ICC = .878; 95% CI 79-93). A slightly lower agreement for PH (ICC = .678; 95% CI 51-81) was noted.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disease with an increasing prevalence worldwide having a significant socioeconomic impact. 1, 2 Magnetic resonance imaging (MRI) is one of the most relevant diagnostic tools in the diagnosis of dementia and has been included into current diagnostic criteria. 3 Imaging findings include the demonstration of certain atrophy patterns and the detection of vascular (co)morbidity supporting the clinical diagnosis of AD or other diseases associated with dementia. 4 Advances in understanding the molecular background of AD pathology strongly support the amyloid cascade hypothesis claiming amyloid beta (Aβ) as the main cause for neuronal death and dysfunction. 5, 6 This dysregulated Aβ metabolism and its pathophysiological importance have led to the development of numerous therapeutic approaches to find potential disease-modifying agents targeting Aβ such as active and passive immunotherapy. 5, 7, 8 Due to the nature of AD, patients are often incapable of signaling adverse effects of these new therapeutic strategies. Consequently, the adverse effects of these new therapies often escape clinical detection. Precise monitoring by other means than clinical observation like MRI have become pivotal tools for detecting adverse events in AD trials. Therefore, neuroradiological monitoring plays an important role in therapeutic trials in AD.
MRI is able to identify so-called amyloid-related imaging abnormalities (ARIA) such as cerebral microbleeds and superficial hemosiderosis deposits, designated as ARIA-hemosiderin (ARIA-H). In addition to these findings related to hemosiderin, MRI hyperintensities indicative of edema and effusion have been described and named ARIA-edema and effusion (ARIA-E). 9 In ARIA-E, three different imaging features can be discerned: parenchymal hyperintensity (PH), sulcal hyperintensity (SH), and gyral swelling (SW). 9, 10 In a minority of cases, these abnormalities were symptomatic primarily associated with headache, confusion, vomiting, or gait disturbance. 9, 11 ARIA-E has been identified most frequently during treatment with amyloid-lowering drugs, especially immunotherapy, but can also occur spontaneously, particularly in patients presenting with cerebral amyloid angiopathy. 9, 12 The clinical consequences of these radiological findings are still unclear; ARIA-E currently remains largely a radiological construct.
For clinical and research purposes, mentioned above, it is imperative to have a robust and validated radiological scoring system that enables the correct radiological classification and grading of ARIA-E, at the time of diagnosis as well as during the treatment. Such a radiological scoring system could assist in the titration of drugs and duration of treatment. As these imaging abnormalities are clinically undetectable in most cases, 9, 13 an MRI scale could be a valuable monitoring tool for the detection of ARIA-E events.
Recently, we proposed a rating scale for ARIA-E, which consists of a simple five-point severity rating for each region affected. Six brain areas used for this rating are the same used on the Age-Related White Matter Changes (ARWMC) rating scale 14 because all of these regions can be also affected by ARIA-E. Our initial assessment showed promising interrater agreement between two experienced raters in a small sample size (n = 10) of ARIA-E patients. 15 So far this scale has not been tested in a group of raters with a more varying neuroradiological experience and who have not been involved in the scale development. Further testing using multiple raters in a larger data set was necessary to validate the results from our initial pilot study; this is mandatory for any rating scale before it can be used with confidence in clinical practice.
The aim of this new study was to validate the use of this novel ARIA-E MRI rating scale in a larger patient group with multiple raters to establish the clinical applicability of the ARIA rating scale.
Methods

Patient Population
All patients included in this study participated in a phase II multicenter, randomized, double-blinded, placebo-controlled, multiple ascending-dose study of bapineuzumab, a humanized anti-Aβ antibody. The study was conducted to evaluate the safety and efficacy of bapineuzumab in 234 patients with mild to moderate AD, with an age ranging from 50 to 85 years. Patients were randomly assigned to receive placebo or ascending doses (.15 mg/kg, .5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg) of intravenous bapineuzumab every 13 weeks with up to six infusions during 18 months. 13, 16 Additional inclusion criteria were a mini-mental state examination (MMSE) score of [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , where a 16-21 MMSE score was categorized as low and a 22-26 score was high.
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Safety scans were performed approximately 6 weeks after each infusion starting at baseline and continuing up to week 71. Imaging included axial fluid-attenuated inversion recovery (FLAIR) sequences to detect ARIA-E. MRI was performed on 1.5 T scanners with 5 mm sections obtained in a 2-dimensional Values are means ±SD (standard deviation).
ARIA-E = amyloid-related imaging abnormalities with edema or effusion; MMSE = mini-mental state examination; DAD = disability assessment for dementia; APOE = apolipoprotein E; n = number of patients.
mode with 1 mm in-plane resolution, as described previously. 16 After study completion, each MRI was re-read centrally by two radiologists who identified the presence of ARIA-E in consensus. 13 For the evaluation sample, we selected 75 patients from the above-mentioned patient group with mild to moderate AD. This included all 29 patients with ARIA-E during the bapineuzumab phase-2 program. Patients were not selected on severity or otherwise to avoid the possible impact of selection bias. The majority of ARIA-E cases were first detected during the study and a minority of ARIA-E was first detected after rereading the MRI's (retrospective analysis). For comparison, we also selected 46 cases without ARIA-E, matched for age, gender, and disease severity. Table 1 shows a detailed summary of the demographic and baseline characteristics of the 75 selected patients. The mean age was 67 years with slightly more females in both groups (overall 62%). Both ARIA-E and non-ARIA-E groups had a mean MMSE score of 21 at enrollment. The ApoE e4 allelic frequencies in the two groups were 78% in ARIA-E and 77% in non-ARIA-E, respectively.
Rater Selection and Qualification
Five raters were invited to participate in this study. All raters were neuroradiologists; two of the raters had experience in the assessment of ARIA-E and were trained using the rating scale (F.B., M.P.W.). 15 The other three raters had no prior experience using this rating scale and they had different backgrounds in terms of qualifications and years of neuroradiological experience. The average experience in neuroradiology was 10 years, ranging from 4 to 25 years. After instruction and training using an online training module, scoring was performed in a blinded fashion with respect to the clinical information and to the scoring of the other raters.
ARIA-E Scoring
Axial FLAIR scan pairs of each patient, including a baseline and follow-up scan, were presented to each rater digitally. At the prestudy drug baseline MRI scans, no ARIA-E was present. On follow-up MRI scan, ARIA-E was present in 29 of the patients. The MRI rating scale for ARIA-E was applied to the ARIA-E = amyloid-related imaging abnormalities with edema or effusion.
FLAIR images using an online viewing tool and the results were documented using a digital scoring form.
ARIA-E Scale
The ARIA-E rating process has been described previously. 15 The rating scale for ARIA-E included both the location and magnitude of presentation of PHs, SHs, and SW. ARIA-E was defined in accordance with the guidelines of the Alzheimer's association research Round Table 2 ). A total score is calculated by summing the individual scores from the six bilateral regions: frontal lobe, parietal lobe, temporal lobe, occipital lobe, central region (basal ganglia, thalamus, internal and external capsules, corpus callosum, insula), and infratentorial region (brainstem and cerebellum). Each region is scored from 0 to 5 based on the spatial extension and multifocally of the abnormality. Each item is rated on the presence or absence of ARIA-E abnormality (score 0 = normal, score 1 = monofocal ࣘ2 cm, score 2 = multifocal ࣘ2 cm, score 3 = any lesion >2 but <4 cm, score 4 = any lesion ࣙ 4 cm, and score 5 = entire lobe). For each scan, a maximum score (range 0-60) is derived by summing up the 12 regional scores, using the highest score in each region for each of the three types of abnormalities (PH, SH, SW). 15 The mean and range for the total sum ARIA-E scores were determined for all scores given by the five raters to provide insight into the variation of ARIA-E MRI presentation in our population.
Scale Tutorial and Image Evaluation
Specific instructions on how to perform and grade the ARIA-E changes according to the rating scale were provided using a web-based instructional system. For introduction and reading purposes, the tutorial was designed specifically with three separate sections. The first section included a brief introduction into ARIA-E providing the theoretical background and image examples. The second section provided an interactive tutorial on the usage of the rating scale form and four training cases, each one with its corresponding baseline and follow-up images, to give the raters a reference for each type of ARIA-E abnormality and how to measure them. The last section was dedicated to the scoring of the data set, which was restricted by a password provided to each rater, and allowed interactive scoring including a measurement tool. Subsequently, the five neuroradiologists had full access to the 75 pair of scans with its corresponding electronic scoring form. All raters were fully blinded to any information regarding treatment and clinical presentation.
Statistical Analysis
To determine agreement between raters, the intraclass correlation coefficient (ICC) was calculated for the combination of PH and SH together (ARIA-E), followed by PH, SH, and SW separately and the combination of the three components. Statistical analyses were conducted using the Statistical Package for the Social Sciences, Version 17, for Windows (SPSS, Chicago, IL, USA).
Results
High agreement was observed between the raters regarding the presence or absence of ARIA-E within individual patients. The ICC for the identification of ARIA-E in the group of patients with and without ARIA-E was .953; 95% (93-96). On average, 4.1% of the 29 cases of ARIA-E were missed by each of the five raters, an average of 1.2 patients per rater. Three cases of ARIA-E were not identified by at least one rater.
Individual patients presented a wide range of ARIA-E manifestations, with varying severity and different spatial extension. Figures 1-3 show the average scores with ranges for minimum and maximum score for each patient for ARIA-E (sum of SH, PH, and SW), SH, and PH, respectively. Visual inspection showed that the ranges per patient were relatively small for ARIA-E scores and SH scores. Larger ranges in scoring were seen in PH scores. Figures 4-7 are examples of cases with discrepant scores.
The range of the ARIA-E score among the 29 scans from the ARIA-E cases was from 1.0 to 44.4, with a mean of 7.4. The range of PH was 0-18.8 (mean 1.2), the range for SH was 0-45.4 (mean 4.0), and for swelling the range was 0-34.8 (mean 7.2). Table 3 presents the median scores by rater. The ARIA-E sensitivity and specificity are shown in Table 4 , with an average sensitivity of 95.6% and specificity of 98.4%.
Interrater agreement (ICC) for SH was .92 (95% CI .85-.95) and for the combined scores of two ARIA-E findings (PH and SH) was .88 (95% CI .79-.93). The overall concordance between the five raters for PH was (ICC) .68 (95% .51-.81) ( Table 5 ). The ICC for SW was .66 (95% CI .48-.80).
Discussion
This interobserver study confirms a high agreement in the identification of ARIA-E cases with less than 5% missed cases of ARIA-E per rater. In addition, it verifies a good interrater agreement for scores of SH and for the combined scores of the two findings used to identify ARIA-E, PH, and SH, using the ARIA-E scale. Combining the PH score with SH score increased the ICC compared to the ICC of PH alone. These results confirm a preliminary, smaller study in 20 patients, 10 with and 10 without ARIA-E 16 and extend our findings to a larger group of less experienced raters. The range of mean scores confirms that the cases rated represent a wide spectrum of radiological severity. Sensitivity and specificity for detection of ARIA-E cases were high across all five raters. We consider the ARIA-E rating scale robust and reproducible to classify ARIA-E in patients undergoing scheduled MRI as a part of drug surveillance. 9, 10, 13 The ICC was numerically higher than in the previous study, perhaps indicating that SH may be more recognizable or that SH is the most common MRI imaging feature of ARIA-E. 10 The relatively lower ICC for PH across the raters in our study is in agreement with the previous reports in a smaller study. 15 This may reflect over or underscoring of the largest crosssectional measurement of the PH, or that the multifocality of PH abnormality was not completely taken into account in the total scoring.
The pathophysiological concept of ARIA is based on an increased vascular permeability associated with Aβ removal from cerebral blood vessels presumably related to amyloid clearance. 9, 13, 17 In both ARIA-H and ARIA-E, the pathophysiology may result from leakage of intravascular contents due to a shift in amyloid. In particular with ARIA-E, the leakage or effusion of proteinaceous fluid is believed to induce MRI changes suggestive of edema and/or sulcal effusions seen as high signal intensities on FLAIR images. 9, 11, 16 Although swelling often accompanies SH, its detection remains more of a challenge due to the often subtle nature of the swelling as shown by the relatively low ICC compared to the other manifestations. In the current study, the ICC for swelling was slightly higher when compared to the previously reported value. Interestingly, the ICC of the combined ARIA-E score (PH + SH) is closer to the SH than the PH value. Probably, raters were more confident about detecting any hyperintensity, than about the individual contributing elements.
Differentiation between SHs and PHs as separate manifestations remains a challenge. The determination of the extension and boundaries for PH may be difficult. 10 Consequently, a possible limitation of the ARIA-E rating scale, despite its relatively simple nature, is that it requires good neuroanatomical knowledge and its consistent application. We consider the scale to be best suited for experienced neuroradiologists. In addition, we believe that to ensure high interobserver reliability in rating ARIA-E cases, the sum score should be used.
Several potential limitations to our study should be considered. Challenges in the assessment of ARIA-E stem from difficulties to detect and score ARIA-E when there are preexisting vascular white matter lesions within areas of PH, or when (predominantly infratentorial) flow artifacts 12 or impaired image quality produce false-positive findings. Figure 6 shows an example of the difficulties to differentiate between vascular white matter lesions and PH. Nonetheless, as mentioned above, sensitivity and specificity remained high across all five readers. A second possible limitation of our study is the fact that our data set is still relatively small and relatively young. However, this is the largest data set of ARIA-E patients in which interrater reliability has been studied prospectively. Another possible limitation is that the frequency or ARIA-E in our sample was higher than would be expected (typically 5-20%). The number of 29, that is, 39% of the total patient group, was chosen as a compromise between approximating the expected frequency of ARIA-E in anti-Aβ antibody studies and maximization of the number of ARIA-E cases for validation.
One more possible limitation is the fact that the ARIA-E scale has not been evaluated with regard to its clinical relevance. In the current data set, many cases were only detected retrospectively and discussion about whether or not ARIA-E should be avoided is ongoing. One of the problems is defining a clinical threshold for ARIA-E has been the lack of a good rating scale. Currently, the ARIA-E rating scale has been used in at least three large phase-3 clinical trials of amyloid-lowering therapies. Similarly, the online training module could easily be made available for other neuroradiologists to ensure consistency in applying the ARIA-E scale.
Fig 7.
This ARIA-E (amyloid-related imaging abnormalities with edema or effusion) patient presented with subtle sulcal hyperintensity (SH) that was recognized as due to ARIA-E based on parenchymal hyperintensity by three of the raters (rater 1, 3, and 5), but only one of the raters scored for SH and swelling (SW) in the left occipital lobe. The top row shows FLAIR (fluid-attenuated inversion recovery) images at baseline. The lower row shows FLAIR images at the follow-up illustrating SH and SW in the left occipital lobe (arrows). ARIA-E = amyloid-related imaging abnormalities with edema or effusion.
In conclusion, the ARIA-E rating scale is a simple and robust visual rating scale that allows for determination of ARIA-E severity and regional categorization of the various manifestations. Since the amount of research in Aβ lowering immunotherapy will likely increase, the need for a rating instrument is apparent. We demonstrated that the MRI rating scale for ARIA-E is both valid and reproducible. Its application may improve the early identification of ARIA-E. It can be completed in a relatively short period of time and may be used ARIA-E = amyloid-related imaging abnormalities with edema or effusion.
for standardized assessment to monitor medical therapy and its management in research studies.
